

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representation of  
The original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> A61K 31/415	<b>A1</b>	<b>(11) International Publication Number:</b> WO 96/36335 <b>(43) International Publication Date:</b> 21 November 1996 (21.11.96)
<b>(21) International Application Number:</b> PCT/EP96/01688 <b>(22) International Filing Date:</b> 23 April 1996 (23.04.96) <b>(30) Priority Data:</b> 9509888.5                      16 May 1995 (16.05.95)                      GB <b>(71) Applicant (for all designated States except US):</b> PHARMACIA S.P.A. [IT/IT]; Via Robert Koch, 1.2, I-20152 Milano (IT). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> BATTISTINI, Carlo [IT/IT]; Via G. Verga, 1, I-20026 Novate Milanese (IT). CIOMBI, Marina [IT/IT]; Via del Molo, 1, I-27020 Torre d'Isola (IT). PIETRA, Francesco [IT/IT]; Via della Fratta, 9, I-55100 Lucca (IT). D'AMBROSIO, Michele [IT/IT]; Via Sabbioni, 22/9, I-38050 Povo (IT). GUERRIERO, Antonio [IT/IT]; Via Malta, 1, I-38100 Trento (IT).	<b>(81) Designated States:</b> AU, BY, CA, CN, HU, JP, KR, KZ, MX, NO, NZ, PL, RU, UA, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
<b>(54) Title:</b> TERPENOIDIC DERIVATIVES (SARCODICTYNS) USEFUL AS ANTITUMOR AGENTS		
<b>(57) Abstract</b> <p>The present invention relates to terpenoidic derivatives, known in the art as Sarcodictyins, for use as therapeutic agents, and to pharmaceutical compositions containing them. In particular, Sarcodictyins can be useful as therapeutic antineoplastic agents in the treatment of cancers in human or animal beings.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

## TERPENOIDIC DERIVATIVES (SARCODICTYINS) USEFUL AS ANTITUMOR AGENTS

5 The present invention relates to terpenoidic derivatives, known in the art as Sarcodictyins (Helvetica Chimica Acta Vol. 70, 1987, 2019-2027 and Helvetica Chimica Acta, Vol. 71, 1988, 964-976), which can be useful as therapeutic agents.

10 A possible therapeutic application of the Sarcodictyins mentioned in the present application was not reported earlier.

In particular, according to the present invention, Sarcodictyins, in view of their cytotoxic activity, can  
15 be of use as therapeutic antineoplastic agents in the treatment of cancers in human or animal beings.

Accordingly, the present invention refers to a compound selected from the group consisting of:

(-) - (4R, 4aR, 7R, 10S, 11S, 12aR, 1Z, 5E, 8Z) - 7, 10-Epoxy-  
20 3, 4, 4a, 7, 10, 11, 12, 12a-octahydro-7-hydroxy-6-(methoxy carbonyl)-1, 10-dimethyl-4-(1-methylethyl)benzo cyclodecen-11-yl (E)-3-(1-Methyl-1H-imidazol-4yl) acrylate (Sarcodictyin A);

(-) - (4R, 4aR, 7R, 10S, 11S, 12aR, 1Z, 5E, 8Z) - 7, 10-Epoxy-6-  
25 (ethoxycarbonyl)-3, 4, 4a, 7, 10, 11, 12, 12a-octahydro-7-hydroxy-1, 10-dimethyl-4-(1-methylethyl)benzocyclodecen-11-yl (E)-3-(1-Methyl-1H, imidazol-4-yl)acrylate

(Sarcodictyin B);

(-) - (3R,4S,4aS,7S,10R,11R,12aS,1Z,5E,8Z) -7,10-Epoxy-3,4,4a,7,10,11,12,12a-octahydro-3,7-dihydroxy-6-(methoxycarbonyl)-1,10-dimethyl-4-(1-methylethyl) benzocyclodecen-11-yl (E)-3-(1-Methyl-1H-imidazol-4-yl)acrylate (Sarcodictyin C);

(-) - (3R,4S,4aS,7S,10R,11R,12aS,1Z,5E,8Z) -3-Acetoxy-7,10-epoxy-3,4,4a,7,10,11,12,12a-octahydro-7-hydroxy-6-(methoxycarbonyl)-1,10-dimethyl-4-(1-methylethyl) benzocyclodecen-11-yl (E)-3-(1-Methyl-1H-imidazol-4-yl)acrylate (Sarcodictyin D);




(+) - (3R,4S,4aS,7S,10R,11R,12aS,1Z,5E,8Z) -7,10-Epoxy-3,4,4a,7,10,11,12,12a-octahydro-3,7-dihydroxy-6-(methoxycarbonyl)-1,10-dimethyl-4-(1-methylethyl) benzocyclodecen-11-yl (Z)-3-(1-Methyl-1H-imidazol-4-yl)acrylate (Sarcodictyin E); and

(+) - (1R,4R,4aR,7R,10S,11S,12aR,2Z,5E,8Z) -7,10-Epoxy-1,4,4a,7,10,11,12,12a-octahydro-1,7-dihydroxy-6-(methoxycarbonyl)-1,10-dimethyl-4-(1-methylethyl) benzocyclodecen-11-yl (E)-3-(1-Methyl-1H-imidazol-4-yl)acrylate (Sarcodictyin F);

for use as a therapeutic agent.

The structural formulae of the above listed compounds is reported in Table 1 below, with reference to the following formulae:

5



10 In the above formulae, the symbol \* represent a chiral center.

Table 1

COMPOUND	(A)	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>
Sarcodictyin A	(A <sub>1</sub> )	Me	H	(E) u
Sarcodictyin B	(A <sub>1</sub> )	Et	H	(E) u
Sarcodictyin C	(A <sub>1</sub> )	Me	OH	(E) u
Sarcodictyin D	(A <sub>1</sub> )	Me	OAC	(E) u
Sarcodictyin E	(A <sub>1</sub> )	Me	OH	(Z) u
Sarcodictyin F	(A <sub>2</sub> )	Me	OH	(E) u

20


In the above Table 1:

the symbol Me means methyl;

the symbol Et means ethyl;

the symbol OAc means OCOCH<sub>3</sub>.

the symbols (E)u and (Z)u represent, respectively, the (E) and (Z) urocanoyl moiety of formula



In particular, the above reported Sarcodictyins A to F may be useful as therapeutic agents in the treatment of cancers in human or animal beings, by virtue of their cytotoxic, antitumor activity. The cancer may be selected from sarcomas, carcinomas, lymphomas, neuroblastomas, melanomas, myelomas, Wilms tumor, leukemias and adenocarcinomas.

15 The Sarcodictyins of the invention may be obtained by isolation from the Mediterranean Stoloniferan Coral "Sarcodictyon Roseum" (*Rolandia rosea*) (Forbes 1847) according to the method reported in *Helvetica Chimica Acta* Vol. 70, 1987, page 2025.

20 The biological activity of the Sarcodictyins of the invention was demonstrated by (a) "in vitro" test to evaluate their activity in promoting the tubulin assembly and (b) "in vitro" test to evaluate their cytotoxic activity both on L 1210 cells and L 1210 cells resistant to  
25 Doxorubicin (L 1210/Dx).

As an example, the activity of Sarcodictyin A (internal code FCE 29123) and Sarcodictyin C (internal code FCE 29119) was evaluated according to the methods described

in tests (a) and (b).

(a) Tubulin assembly test

Calf brain tubulin was prepared by two cycles of assembly-disassembly (Shelanski M.L., Gaskin F. and  
5 Cantor C.R., Proc. Natl.Acad.Sci. U.S.A. 70, 765-768, 1973) and stored in liquid nitrogen in MAB (0.1 M MES, 2.5 mM EGTA, 0.5 mM MgSO<sub>4</sub>, 0.1 mM EDTA, 0.1 mM DTT, pH 6.4).

All the experiments were carried out on protein stored  
10 for less than 4 weeks.

Before each experiment, tubulin was kept 30 min at 4°C. Assembly was monitored by the method of Gaskin et al. (Gaskin F., Cantor C.R. and Shelanski M.L., J.Molec.Biol. 89, 737-758, 1974).

15 The cuvette (1 cm path) containing tubulin (1mg/ml) and 1 mM GTP was shifted to 37°C and continuous turbidity measurements were made at 340 nm on a Perkin-Elmer 557 double wavelength, double beam spectrophotometer equipped with an automatic recorder and a  
20 thermostatically regulated sample chamber.

After 30 minutes, 4 mM CaCl<sub>2</sub> was added and depolymerisation was measured for 10 minutes as decreased turbidity.

At regular intervals of 15 minutes scaled doses of the  
25 tested compounds were added and variations in the turbidity were monitored.

Data are expressed as percentage of repolymerization



induced by the tested compounds.

The obtained results are reported in Table 2

Table 2

5	<b>COMPOUND</b>	<b>dosage (<math>\mu</math>M)</b>	<b>tubulin assembly (%)</b>
	Sarcodictyin A	4	70
	(FCE 29123)	40	162
	Sarcodictyin C	3.9	112
	(FCE 29119)	39	173

10

The above tabulated data clearly demonstrate that the tested Sarcodictyins are able to promote tubulin repolymerization even in the presence of CaCl<sub>2</sub>, which usually inhibits tubulin assembly.

15 As it is well known in the art, microtubules are among the most strategic subcellular targets of anticancer chemotherapeutics (Rowinsky et al., Review, Vol. 82, No. 15, August 1, 1990).

Unlike classical antimicrotubule agents like colchicine  
20 and the vinca alkaloids which induce depolymerization of microtubules, Sarcodictyins seem to possess a mechanism of action similar to that of Taxol, one of the most interesting anticancer agents emerged from the screening of natural products, by inducing tubulin polymerization  
25 and forming extremely stable and nonfunctional microtubules.

Sarcodictyins can therefore be useful as therapeutic antineoplastic agents in the treatment of cancers in human or animal beings, in view of their ability to catalize rapid microtubule formation and stabilization which cause suspension of cellular division in the tumor cells.

(b) Cell cultures and drug sensitivity assay

L1210 and L1210/DX (Doxorubicin resistant) murine leukemia cell lines were grown in vitro as a stationary suspension culture in RPMI 1640 medium (GIBCO, Grand island, NY) supplemented with 10% fetal calf serum (Flow, Irvine, UK), 2 mM L-glutamine (Gibco Europe, Glasgow, UK), 10  $\mu$ M  $\beta$ -mercaptoethanol, 100 Units/ml penicillin and 100  $\mu$ g/ml streptomycin.

Exponentially growing cells were seeded ( $1 \times 10^5$  cell/ml) in 12-well/plates (Costar, Cambridge, MA) and various concentrations of tested compounds were added immediately after seeding.

The plates were incubated at 37°C in a humidified, 5% CO<sub>2</sub> atmosphere for 48 hr.

Inhibition of cell growth was evaluated by counting surviving cells in a ZBI Coulter Counter (Hialeah, FL). The 50% inhibitory concentration (IC<sub>50</sub>) was calculated on the derived concentration-response curve. For each tested compound concentration, duplicate cultures were used.

The obtained results are reported on Table 3

Table 3

Compound	ID <sub>50</sub> (nM) *		R.I
	L1210	L1210/DX	
Sarcodictyin A (FCE 29123)	539.2 ± 97.7	754.5 ± 80.3	1.4
Sarcodictyin C (FCE 29119)	408.5 ± 21.3	5787.0 ± 182.6	14.2

\*48 h treatment

10 R.I. = Resistance index =  $\frac{ID_{50} \text{ L1210/DX}}{ID_{50} \text{ L1210}}$

As evident from the above tabulated data, Sarcodictyins exhibit a good "in vitro" cytotoxic activity both on L1210 and L1210 cells resistant to Doxorubicin (L1210/Dx).

In view of their effectiveness on L 1210/DX cells, the Sarcodictyins can be useful in the treatment of a tumor resistant to a chemotherapeutic agent, such as, e.g., an anthracycline glycoside, in particular Doxorubicin.

20 A human or animal being can be treated by a method which comprises the administration thereto of a pharmaceutically effective amount of a compound selected from Sarcodictyin A, Sarcodictyin B, Sarcodictyin C, Sarcodictyin D, Sarcodictyin E and Sarcodictyin F.

25 The condition of the human or animal being can thereby

be improved.

The Sarcodictyins of the invention can be administered in a variety of dosage forms, e.g. orally, in the form of tables, capsules, sugar or film coated tablets, liquid solutions or suspensions; rectally in the form of suppositories; parenterally, e.g. intramuscularly, or by intravenous injection or infusion.

The dosage depends on the age, weight, conditions of the patient and on the administration route; for example, the dosage adopted for oral administration to adult humans, e.g., for the representative compound of the invention FCE 29213 (Sarcodictyin A) may range from about 0.01 g to about 1 g per day.

The invention includes also pharmaceutical compositions comprising a Sarcodictyin of the invention as an active principle in association with a pharmaceutically acceptable excipient (which can be a carrier or a diluent).

The pharmaceutical compositions containing the compounds of the invention are usually prepared following conventional methods and are administered in a pharmaceutically suitable form.

For example, the solid oral forms may contain, together with the active compound, diluents, e.g. lactose, destrose, saccharose, cellulose, corn starch or potato starch; lubricants, e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene

glycols; binding agents, e.g. starches, arabic gums, gelatin, methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone; disaggregating agents, e.g. a starch, alginic acid, alginates or sodium starch glycolate; effervescing mixtures; dyestuffs; sweeteners; 5 wetting agents such as lecithin, polysorbates, laurylsulphates; and, in general, non-toxic and pharmacologically inactive substances used in pharmaceutical formulations.

10 Said pharmaceutical preparations may be manufactured in known manner, for example by means of mixing, granulating, tableting, sugar-coating, or film-coating processes.

The liquid dispersions for oral administration may be, 15 e.g., syrups, emulsions and suspensions.

The syrups may contain as carrier, for example, saccharose or saccharose with glycerine and/or mannitol and/or sorbitol.

The suspensions and the emulsions may contain as 20 carrier, for example, a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol.

The suspension or solution for intramuscular injections may contain, e.g., together with the active compound, a 25 pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol, and, if desired, a suitable amount of lidocaine

hydrochloride.

The solutions for intravenous injections or infusion may contain as carrier, for example, sterile water or preferably they may be in the form of sterile, aqueous, isotonic saline solutions.

The suppositories may contain together with the active compound a pharmaceutically acceptable carrier, e.g. cocoa butter, polyethylene glycol, a polyoxyethylene sorbitan fatty acid ester surfactant or lecithin.

CLAIMS

1. A compound selected from the group consisting of:

(-)-(4R,4aR,7R,10S,11S,12aR,1Z,5E,8Z)-7,10-Epoxy-3,4,4a,7,10,11,12,12a-octahydro-7-hydroxy-6-(methoxycarbonyl)-1,10-dimethyl-4-(1-methylethyl)benzocyclodecen-11-yl (E)-3-(1-Methyl-1H-imidazol-4-yl)acrylate (Sarcodictyin A);

(-)-(4R,4aR,7R,10S,11S,12aR,1Z,5E,8Z)-7,10-Epoxy-6-(ethoxycarbonyl)-3,4,4a,7,10,11,12,12a-octahydro-7-hydroxy-1,10-dimethyl-4-(1-methylethyl)benzocyclodecen-11-yl (E)-3-(1-Methyl-1H-imidazol-4-yl)acrylate (Sarcodictyin B);

(-)-(3R,4S,4aS,7S,10R,11R,12aS,1Z,5E,8Z)-7,10-Epoxy-3,4,4a,7,10,11,12,12a-octahydro-3,7-dihydroxy-6-(methoxycarbonyl)-1,10-dimethyl-4-(1-methylethyl)benzocyclodecen-11-yl (E)-3-(1-Methyl-1H-imidazol-4-yl)acrylate (Sarcodictyin C);

(-)-(3R,4S,4aS,7S,10R,11R,12aS,1Z,5E,8Z)-3-Acetoxy-7,10-epoxy-3,4,4a,7,10,11,12,12a-octahydro-7-hydroxy-6-(methoxycarbonyl)-1,10-dimethyl-4-(1-methylethyl)benzocyclodecen-11-yl (E)-3-(1-Methyl-1H-imidazol-4-yl)acrylate (Sarcodictyin D);

(+)-(3R,4S,4aS,7S,10R,11R,12aS,1Z,5E,8Z)-7,10-Epoxy-3,4,4a,7,10,11,12,12a-octahydro-3,7-dihydroxy-6-(methoxycarbonyl)-1,10-dimethyl-4-(1-methylethyl)benzocyclodecen-11-yl (Z)-3-(1-Methyl-1H-imidazol-4-yl)acrylate (Sarcodictyin E); and

(+) - (1R, 4R, 4aR, 7R, 10S, 11S, 12aR, 2Z, 5E, 8Z) - 7, 10-Epoxy-1, 4, 4a, 7, 10, 11, 12, 12a-octahydro-1, 7-dihydroxy-6-(methoxycarbonyl)-1, 10-dimethyl-4-(1-methylethyl)benzocyclodecen-11-yl (E)-3-(1-Methyl-1H-imidazol-4-yl)acrylate (Sarcodictyin F);

for use as a therapeutic agent.

2. A compound as claimed in claim 1, for use as enhancer of tubulin assembly which causes suspension of cellular division in the tumor cells.

10 3. A compound as claimed in claim 1, for use as antitumor agent.

4. A compound as claimed in claim 1, for use in the treatment of a tumor resistant to a chemotherapeutic agent.

15 5. A compound according to claim 4 wherein the chemotherapeutic agent is an anthracycline glycoside.

6. A compound according to claim 5 wherein the anthracycline glycoside is Doxorubicin.

7. Use of a compound as claimed in claim 1, in the  
20 preparation of a medicament for use as a therapeutic antineoplastic agent in the treatment of cancers in human or animal beings.

8. A pharmaceutical composition which comprises as an active ingredient a compound as claimed in claim 1 and  
25 a pharmaceutically acceptable carrier and/or diluent.

9. A pharmaceutical composition as claimed in claim 8, for use as enhancer of tubulin assembly which causes



suspension of cellular division in the tumor cells.

10. A pharmaceutical composition as claimed in claim 8, for use as a therapeutic antineoplastic agent in the treatment of cancers in human or animal beings.

5 11. A pharmaceutical composition as claimed in claim 8, for use in the treatment of tumors resistant to a chemotherapeutic agent.

12. A pharmaceutical composition according to claim 11, wherein the chemotherapeutic agent is an anthracycline glycoside.

10 13. A pharmaceutical composition according to claim 12 wherein the anthracycline glycoside is Doxorubicin.

# INTERNATIONAL SEARCH REPORT

In .tional Application No.  
PCT/EP 96/01688

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 A61K31/415

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>HELV.CHIM.ACTA, vol. 70, no. 8, 1987, pages 2019-27, XP000601545 D'AMBROSIO ET AL.: "Sarcodictyin A and Sarcodictyin B, novel diterpenoidic alcohols esterified by (E)-N(1)-methylurocanic acid. Isolation from the Mediterranean Stolonifer Sarcodictyon Roseum" cited in the application see the whole document</p> <p style="text-align: center;">--- -/--</p>	1-13

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

\* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

9 September 1996

Date of mailing of the international search report

16.09.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+ 31-70) 340-3016

Authorized officer

Gerli, P

# INTERNATIONAL SEARCH REPORT

In. tional Application No  
PCT/EP 96/01688

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>HELV.CHIM.ACTA, vol. 71, 1988, pages 964-976, XP002012952 D'AMBROSIO ET AL.: "Isolation from the Mediterranean Stoloniferan of Sarcodictyin C,D,E and F, novel diterpenoidic alcohols esterified by (E) or (Z)-N(1)-methylurocanic acid. Failure of the carbon-skeleton type as a classification criterion" cited in the application see the whole document ---</p>	1-13
A	<p>PROSTAGLANDINS, vol. 36, no. 5, 1988, pages 621-30, XP000601531 HONDA ET AL.: "Structure requirements for antiproliferative and cytotoxic activities of marine coral prostanoids from the Japanese stolonifer Clavularia Viridis against human myeloid leukemia cells in culture" see the whole document -----</p>	1-13